1. 1) Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol., 19, 2587–2595 (2001).
2. 2) Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol., 19, 1523–1529 (2008).
3. 3) Shinada M, Okuda Y, Mikame Y, Kezuka C, Suga R, Saitou T, Kobayashi N, Hoshi C, Imai Y. Efficacy and safety of trastuzumab biosimilars in ombination with pertuzumab. Gan To Kagaku Ryoho, 50, 615–618 (2023).
4. 4) Sato K, Kohgo Y. Infusion reactions. Gan To Kagaku Ryoho, 35, 1671–1674 (2008).
5. 5) Okuda Y, Mikame Y, Shinada M, Yamaguchi H, Fujii H, Sudoh T. Assessment of efficacy and adverse effects of trastuzumab biosimilar in gastric cancer. Gan To Kagaku Ryoho, 47, 1341–1344 (2020).